Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Human BCMA Targeted T Cells in R/R Multiple Myeloma
NCT04003168Phase 1Unknown
- Sponsor
- Shanghai HRAIN Biotechnology
- Start
- Jul 2019
- Primary completion
- Jul 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRC0202 in multiple myeloma (MM), sponsored by Shanghai HRAIN Biotechnology. Primary endpoint: Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0. Status: unknown.
02
Drugs
HRC0202
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04003168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04003168.